Some existing anti-cancer drugs may act in part by targeting RNA
Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti-cancer drugs may work, in part, by binding tightly to RNA, the regulators of the basic activities of life within cells. The research offers another approach for tackling diseases that have been considered "undruggable," including amyotrophic lateral sclerosis (ALS), muscular dystrophy, cystic fibrosis and certain cancers.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
More News: ALS | Cancer | Cancer & Oncology | Cystic Fibrosis | Muscular Dystrophy | Pharmaceuticals | Reflex Sympathetic Dystrophy